An Illustrated Guide to Fire in Central Oregon Forests

This pictorial guide is primarily intended to serve as a backdrop for field tours of central Oregon that involve topics surrounding wildland fire. It also is designed to provide an overview of the role of fire in the major ecosystems characteristic of this region. Topics covered include fire history, fire regimes, current fire conditions, fire behavior, fire threats to natural resources, fuel treatments, interactions with the public, and future challenges and management options. A list of key references and glossary are also included

Rituximab in refractory Vogt–Koyanagi–Harada disease

IntroductionVogt–Koyanagi–Harada (VKH) prognosis depends on early recognition and treatment; chronic disease may be developed when either delayed or inadequate treatment is performed, whereas other cases despite correct treatment are refractory to different drugs and also become chronic. We report a case of refractory VKH controlled with rituximab treatment.Case reportA 41-year-old female with painful visual loss and headache was examined. (VA 0.4 in RE and hand movements (HM) in LE). Retinal examination demonstrated multiple serous retinal detachments in both eyes. High-dose oral steroids were started, followed by progressive tapering of prednisone. New acute anterior and posterior relapses were achieved, and other immunommodulators were progressively added—new high-dose steroid treatment, adalimumab, cyclosporine, and methotrexate—but patient had new anterior and posterior recurrences associated with tinnitus and headache. Thus, an infusion of 1 g of rituximab was administered after 15 months follow-up; the VA was 0.2 in RE and counting fingers in LE. Three additional doses of 1 g each were administered 1, 6, and 16 months later. We have achieved a final VA after 34 months follow-up of 0.2 in RE and HM in LE, with definitive control of inflammation, without acute relapses since rituximab was administered.ConclusionAfter searching PubMed/Medline, this is the first report of VKH disease treated with rituximab. Additional studies are warranted to confirm the efficacy of this new approach for inflammatory control in refractory cases of VKH disease

Survival and growth of Douglas-fir seed sources in the Hospital Tract rangewide source archive plantation

"In 1954, Dr. Helge Irgens-Moller initiated a rangewide collection of seed and seedlings of Douglas-fir (Pseudotsuga menziesii (Mirb.) Franco). Nearly 700 trees or stands were sampled in 10 western states, Canada, and Mexico. From 1957 to 1971, 639 of these collections were planted in the Hospital Tract Rangewide Source Archive near Corvallis, Oregon. By 1989, the trees were from 20 to 34 years old; it became apparent that thinning the archive would be necessary in order to preserve the slower growing sources. This prompted growth and survival measurements and a complete inventory of the archive. Overall survival for all years of planting was greater than 80 percent for coastal sources (var. menziesii), but less than 60 percent for interior sources (var. glauca). The average diameter at breast height (DBH) of surviving trees was 29.05 cm; the range was from 1.2 to 61 cm. An analysis of the 1957 and 1961 plantings revealed that local and other low elevation coastal sources had the fastest growth and highest survival in the archive. High elevation sources from the Cascade Range had significantly smaller DBH, but higher survival. Southern interior sources from Arizona and New Mexico had the smallest DBH and lowest survival; northern interior sources from Montana and Idaho were intermediate in survival and DBH. Geographical variation among sources in the Hospital Tract was associated with environmental gradients, supporting the previously held conclusion that much of the genetic variation on a geographical scale in Douglas-fir is the result of adaptation."--Summar

Response of young Douglas-fir to 16 years of intensive thinning

A 20-year-old Douglas-fir [Pseudotsuga menziesii (Mirb.) Franco] stand in the Oregon Coast Range was thinned from about 1,700 to about 350 trees/ac. Subsequent thinnings, under eight different regimes, occurred at ages 23, 27, 30, and 32. Average net periodic cubic-volume growth was strongly influenced by thinning regime, varying from about 220 ft /ac/yr (heavy thinning age 30) to over 550 ft /ac/yr (controls age 23). The results indicate that young Douglas-fir on productive sites (site index 160 to 170 ft at 100 years) are extremely adaptable and will respond to frequent thinnings of various intensities. Three representative treatments (after thinning at age 32) and the controls were projected and optimized with dynamic programming for two financial analyses. Adjusting rotation or commercial thinning can compensate for lack of early stand management or heavy early thinning

Efficient Photodynamic Therapy against Gram-Positive and Gram-Negative Bacteria Using THPTS, a Cationic Photosensitizer Excited by Infrared Wavelength

The worldwide rise in the rates of antibiotic resistance of bacteria underlines the need for alternative antibacterial agents. A promising approach to kill antibiotic-resistant bacteria uses light in combination with a photosensitizer to induce a phototoxic reaction. Concentrations of 1, 10 and 100µM of tetrahydroporphyrin-tetratosylat (THPTS) and different incubation times (30, 90 and 180min) were used to measure photodynamic efficiency against two Gram-positive strains of S.aureus (MSSA and MRSA), and two Gram-negative strains of E.coli and P.aeruginosa. We found that phototoxicity of the drug is independent of the antibiotic resistance pattern when incubated in PBS for the investigated strains. Also, an incubation with 100µM THPTS followed by illumination, yielded a 6lg (≥99.999%) decrease in the viable numbers of all bacteria strains tested, indicating that the THPTS drug has a high degree of photodynamic inactivation. We then modulated incubation time, photosensitizer concentration and monitored the effect of serum on the THPTS activity. In doing so, we established the conditions to obtain the strongest bactericidal effect. Our results suggest that this new and highly pure synthetic compound should improve the efficiency of photodynamic therapy against multiresistant bacteria and has a significant potential for clinical applications in the treatment of nosocomial infections

TRY plant trait database - enhanced coverage and open access

Plant traits-the morphological, anatomical, physiological, biochemical and phenological characteristics of plants-determine how plants respond to environmental factors, affect other trophic levels, and influence ecosystem properties and their benefits and detriments to people. Plant trait data thus represent the basis for a vast area of research spanning from evolutionary biology, community and functional ecology, to biodiversity conservation, ecosystem and landscape management, restoration, biogeography and earth system modelling. Since its foundation in 2007, the TRY database of plant traits has grown continuously. It now provides unprecedented data coverage under an open access data policy and is the main plant trait database used by the research community worldwide. Increasingly, the TRY database also supports new frontiers of trait-based plant research, including the identification of data gaps and the subsequent mobilization or measurement of new data. To support this development, in this article we evaluate the extent of the trait data compiled in TRY and analyse emerging patterns of data coverage and representativeness. Best species coverage is achieved for categorical traits-almost complete coverage for 'plant growth form'. However, most traits relevant for ecology and vegetation modelling are characterized by continuous intraspecific variation and trait-environmental relationships. These traits have to be measured on individual plants in their respective environment. Despite unprecedented data coverage, we observe a humbling lack of completeness and representativeness of these continuous traits in many aspects. We, therefore, conclude that reducing data gaps and biases in the TRY database remains a key challenge and requires a coordinated approach to data mobilization and trait measurements. This can only be achieved in collaboration with other initiatives

Ocular inflammatory events following COVID-19 vaccination: a multinational case series

Background: Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions. Methods: Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021. Results: Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19–84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1–14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%). Conclusion: Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome